NL-OMON23931已完成4 期
Mebeverine in children with IBS or FAP-NOS
Mylan B.V.0 个研究点目标入组 325 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 325
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 17（—）
入选标准
- •All children aged between 12 and 18 years diagnosed with irritable bowel syndrome or functional abdominal pain – not otherwise specified according to the Rome IV criteria will be invited to participate. The Rome IV criteria form the internationally accepted standard for defining functional gastrointestinal disorders like irritable bowel syndrome and functional abdominal pain – not otherwise specified.1 Before inclusion, all patients undergo routine laboratory testing to exclude underlying organic disorders: complete blood cell count, C-reactive protein, celiac screening (anti-transglutaminase antibodies and IgA), fecal screening on Giardia lamblia if patient presents with diarrhea, and on calprotectin in case an Inflammatory Bowel Disease is suspected. The need for further diagnostic testing is left to the discretion of the treating physician. Finally, according to a recently published guideline by the Rome Foundation for the design of pharmacological clinical trials in children, patients are required to have an average daily pain rate of =2 on the Wong Baker Faces Pain Scale. This is a validated pain scale to measure pain intensity. In addition, Informed Consent by both parents and by children aged = 12 years is a necessity before children can be included in the study.
排除标准
- •Current treatment by another health care professional for abdominal symptoms • Previous use of mebeverine • Known hypersensitivity to the active substance or to any of the excipients ((magnesium stearate, polyacrylate dispersion , talc, hypromellose, methacrylic acid – ethyl acrylate copolymer (1:1) dispersion , glycerol triacetate, gelatine, titanium dioxide (E171), shellac (E904), propylene glycol, ammonia solution (concentrated), potassium hydroxide, iron oxide black (E172)). • Unintentional weight loss greater than or equal to 5% of their body weight within the last 3 months • Gastrointestinal blood loss • Recurrent or unexplained fevers • Decreased growth velocity • History of previous abdominal surgeries in the past 3 months • Rome IV criteria diagnosis of functional constipation • Children who tested positive for bacterial or parasites infections • Carbohydrate malabsorption, diagnosed either clinically (2 weeks exclusion diet with resolution of symptoms) or with proper testing (breath test). Children with carbohydrate intolerance who continue to have IBS symptoms while on an exclusion diet can still be included • Significant chronic health condition requiring specialty care (e.g., lithiasis, ureteropelvic junction obstruction, sickle cell, cerebral palsy, hepatic, hematopoietic, renal, endocrine, or metabolic diseases) that could potentially impact the child’s ability to participate or confound the results of the study • Known diagnosis of cystic fibrosis • Known diagnosis of porphyria • Known concomitant organic gastrointestinal disease • Current use of drugs which influence gastrointestinal motility, such as erythromycin, azithromycin, butyl scopolamine, domperidone, peppermint oil capsules, and Iberogast. • Insufficient knowledge of the Dutch language • Pregnancy or current lactation. Women with childbearing potential must have a negative urine pregnancy test within 7 days prior to first dose of study treatment
研究者
相似试验
尚未招募
4 期
In children with inflammatory bowel disease and iron deficiency, does intravenous iron therapy with Ferric Carboxymaltose significantly improve cognitive function, quality of life and iron status.Paediatric Inflammatory Bowel DiseaseIron deficiency anaemiaIron deficiency without anaemiaOral and Gastrointestinal - Inflammatory bowel diseaseACTRN12613000751774Gastroenterology Department, Royal Children's Hospital - Brisbane50
已完成
2 期
Rifaximin for the Treatment of Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00259155Cedars-Sinai Medical Center92
已完成
4 期
Efficacy and Safety of Meteospasmyl® in Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00542295Laboratoires Mayoly Spindler400
已完成
不适用
Efficacy of a Low FODMAP Diet in IBS Children and Impact on Urinary and Faecal MetabolomeIBSFunctional Gastrointestinal DisordersNCT06618677University of Bari70
招募中
2 期
Dabrafenib and Trametinib in pediatric patients with refractory advanced Solid Tumors with BRAF V600 mutations12 months to 15 year- old patients with unresectable or refractory solid cancer with BRAF V600JPRN-jRCTs011220017Kinoshita Ichiro28